Dongbang Medical Co., Ltd (KOSDAQ:240550)
South Korea · Delayed Price · Currency is KRW 5,580.00
-90.00 (-1.59%)
Sep 11, 2026, 3:30 PM KST
Dongbang Medical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 125,117 | 113,537 | 105,114 | 90,875 | 81,408 | |
Revenue Growth | 15.52% | 8.01% | 15.67% | 11.63% | - |
Cost of Revenue | 79,540 | 73,394 | 71,020 | 60,134 | 58,887 |
Gross Profit | 45,577 | 40,143 | 34,094 | 30,741 | 22,520 |
Selling, General & Admin | 19,403 | 18,137 | 14,821 | 11,972 | 11,240 |
Research & Development | 2,594 | 3,287 | 2,591 | 2,100 | 1,798 |
Amortization of Goodwill & Intangibles | 251.88 | 254.1 | 252.13 | 241.12 | 370.93 |
Other Operating Expenses | 624.23 | 534.74 | 361.01 | 286.9 | 572.2 |
Operating Expenses | 24,377 | 23,891 | 18,618 | 13,560 | 16,961 |
Operating Income | 21,200 | 16,252 | 15,476 | 17,182 | 5,560 |
Interest Expense | -1,119 | -1,137 | -1,956 | -2,613 | -1,308 |
Interest & Investment Income | 401 | 404.75 | 201.48 | 86.23 | 40.72 |
Earnings From Equity Investments | - | - | - | 45.53 | - |
Currency Exchange Gain (Loss) | 816.13 | -188.94 | 1,080 | -202.05 | 734.38 |
Other Non Operating Income (Expenses) | -8.09 | 225.63 | -9,270 | -1,182 | 1,159 |
EBT Excluding Unusual Items | 21,290 | 15,556 | 5,532 | 13,317 | 6,186 |
Gain (Loss) on Sale of Investments | -1,577 | -1,455 | -727.67 | -709.31 | -537.95 |
Gain (Loss) on Sale of Assets | 267.52 | 181.98 | 1,986 | -102.65 | -28.47 |
Pretax Income | 19,980 | 14,283 | 6,791 | 12,505 | 5,619 |
Income Tax Expense | 4,366 | 2,840 | 3,663 | 2,771 | 2,300 |
Earnings From Continuing Operations | 15,614 | 11,442 | 3,127 | 9,734 | 3,320 |
Minority Interest in Earnings | 504.43 | 260.91 | -212.84 | 40.46 | -127.95 |
Net Income | 16,119 | 11,703 | 2,914 | 9,775 | 3,192 |
Net Income to Common | 16,119 | 11,703 | 2,914 | 9,775 | 3,192 |
Net Income Growth | 72.79% | 301.58% | -70.19% | 206.26% | - |
Shares Outstanding (Basic) | 21 | 20 | 16 | 15 | 15 |
Shares Outstanding (Diluted) | 21 | 21 | 16 | 17 | 15 |
Shares Change | 14.14% | 28.29% | -7.51% | 17.90% | - |
EPS (Basic) | 772.53 | 572.40 | 180.07 | 658.62 | 215.05 |
EPS (Diluted) | 765.27 | 564.00 | 180.07 | 617.82 | 215.05 |
EPS Growth | 50.10% | 213.20% | -70.85% | 187.29% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -6,235 | -2,505 | 5,408 | 1,811 | 4,379 |
Free Cash Flow Per Share | -296.12 | -120.64 | 334.19 | 103.53 | 295.08 |
Gross Margin | 36.43% | 35.36% | 32.44% | 33.83% | 27.66% |
Operating Margin | 16.94% | 14.31% | 14.72% | 18.91% | 6.83% |
Profit Margin | 12.88% | 10.31% | 2.77% | 10.76% | 3.92% |
Free Cash Flow Margin | -4.98% | -2.21% | 5.15% | 1.99% | 5.38% |
EBITDA | 28,570 | 23,273 | 21,640 | 22,630 | 10,832 |
EBITDA Margin | 22.84% | 20.50% | 20.59% | 24.90% | 13.31% |
D&A For EBITDA | 7,370 | 7,021 | 6,164 | 5,448 | 5,272 |
EBIT | 21,200 | 16,252 | 15,476 | 17,182 | 5,560 |
EBIT Margin | 16.94% | 14.31% | 14.72% | 18.91% | 6.83% |
Effective Tax Rate | 21.85% | 19.89% | 53.95% | 22.16% | 40.92% |
Advertising Expenses | - | 1,944 | 1,446 | 994.74 | 482.08 |